News|Videos|December 11, 2023
Data From the AtTEnd: Study: Atezolizumab Plus Carboplatin and Paclitaxel for Treatment of Advanced Endometrial Cancer
Drs Powell and Backes discuss additional immunotherapy trial results from ESMO 2023 including AtTEnd and DUO-E, noting differences across trials likely due to patient population composition rather than drug differences, and need for caution with PARP inhibitor maintenance.
Advertisement
Episodes in this series
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Therapy Designation to JBS-003 for Radiation De-Escalation in HPV+ Oropharyngeal Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma
4
A New Player in the Adjuvant Setting? GLP-1 Agonists and the Fight Against Breast Cancer Metastasis
5